FORTIS HEALTHCARE LTD.

IHH Healthcare Berhad has issued a media statement clarifying its position regarding the forensic audit ordered by the Delhi High Court concerning Fortis Healthcare. IHH asserts that its 2018 acquisition of a 31% stake in Fortis for INR 4,000 crore was conducted through a transparent, regulated process, with all necessary approvals. The company emphasized that no secondary shares were acquired from the former promoters, and IHH was not involved in their disputes. IHH stated its full cooperation with the audit and reiterated its commitment to India as a key strategic market, planning to increase its stake in Fortis to 51% and expand bed capacity.

Fortis Healthcare Ltd announced that the Hon'ble Supreme Court, in an order dated September 25, 2026, has disposed of a Special Leave Petition. The petition challenged a Delhi High Court order concerning a forensic audit and certain observations made against the company. The Supreme Court has allowed the forensic audit to proceed but clarified that the observations in the High Court's judgment are tentative and should not influence the audit's independent conduct or outcome. The company reiterated that it is not a party to the underlying dispute between Daiichi Sankyo and the Singh Brothers, nor is it a judgment debtor or garnishee. Fortis also highlighted its new promoter, IHH Healthcare Berhad, took over in November 2018 after the erstwhile promoters ceased their association.

Fortis Healthcare Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in effect from October 1, 2026, and will remain open until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ended September 30, 2026. This measure is in line with the company's policy and code of conduct for the prevention of insider trading, ensuring fair market practices.

Fortis Healthcare's promoter shareholder, Northern TK Venture Pte Ltd (NTK), an indirect subsidiary of IHH Healthcare, has filed an appeal with the Tokyo High Court against a September 10, 2026 judgment by the Tokyo District Court. NTK believes the judgment warrants appellate review. IHH Healthcare claims losses due to delays in mandatory tender offer approvals for its Fortis Healthcare acquisition, stemming from a dispute between Daiichi Sankyo and judgment debtors, to which IHH was not a party. IHH reaffirms its commitment to India as a strategic market and plans to increase its stake in Fortis to 51% in the next three to five years.

Fortis Hospotel Limited, a wholly-owned subsidiary of Fortis Healthcare Ltd, has signed definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital (SLJ Society). The agreement is for providing healthcare and medical services and facilitating the construction, upgrade, and operation of a 400+ bedded super specialty hospital in Ashok Vihar, New Delhi. Fortis Hospotel will have exclusive rights to provide specified inpatient healthcare services and specialized equipment for a committed term of 29 years, with an option to extend. The hospital is expected to commence operations in 3-4 years. Fortis will also provide a phased loan to SLJ Society for construction and upgradation. This collaboration aims to enhance access to quality healthcare in North-West Delhi.

Fortis Hospotel Limited, a wholly-owned subsidiary of Fortis Healthcare Ltd, has signed definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital (SLJ Society). The agreement facilitates the construction, upgrade, and operation of a 400+ bed super specialty hospital in Ashok Vihar, New Delhi. Fortis Hospotel will provide healthcare services and clinical manpower under a 29-year Healthcare Services Agreement, with an option to extend. SLJ Society will own and develop the hospital, while Fortis will provide a phased loan for construction. The hospital is expected to commence operations in 3-4 years and will offer tertiary and quaternary healthcare services, including provisions for Economically Weaker Sections.

Fortis Healthcare Limited has filed a Special Leave Petition (SLP) before the Hon'ble Supreme Court of India. This action is in response to a judgment passed by the Hon'ble Delhi High Court on August 31, 2026. The SLP, filed on September 16, 2026, pertains to the ongoing dispute with Daiichi Sankyo Company, Limited, specifically concerning applications related to O.M.P.(EFA)(COMM.) 6/2016. The company has previously disclosed details of the order on September 01, 2026. No specific financial implications or quantum of claims are currently disclosed as N/A.

Fortis Healthcare's promoter shareholder, Northern TK Venture Pte Ltd (NTK), has lost its material litigation against Daiichi Sankyo Company, Limited before the Tokyo District Court in Japan. The court dismissed all of NTK's claims and ordered NTK to bear the litigation costs. This development follows numerous previous announcements regarding the ongoing legal proceedings. IHH Healthcare Berhad, which is associated with the transaction, made the announcement on September 10, 2026, via the Malaysian and SGX stock exchanges. Fortis Healthcare will continue to inform stakeholders of any material developments.

Fortis Healthcare Ltd announced that a single judge bench of the Hon'ble Delhi High Court has ordered the appointment of a forensic auditor. The audit will investigate the dissipation of shareholding by the erstwhile promoters, the Singh Brothers, and the subsequent change in the company's control. The court has not imposed any liability, penalty, or fine on Fortis Healthcare, which was not a party to the original dispute. The company is reviewing the order with legal counsel to determine the appropriate course of action. This development follows earlier disclosures dated September 23, 2022. The event occurred on August 31, 2026, at 04:31 PM (IST).

Fortis Healthcare Limited has been assigned an ESG Rating for FY 2025-26 by Crisil ESG Ratings & Analytics Ltd. The company received ratings of 'Crisil ESG 66' and 'Crisil Core ESG 72', both categorized as 'Strong'. This rating was assigned by Crisil based on publicly available information and data shared by the company, without direct engagement from Fortis Healthcare. The rating reflects the company's performance across Environmental, Social, and Governance parameters. Fortis Healthcare has voluntarily disclosed this information and uploaded it on its website.